Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy


      Understanding prostate-specific antigen (PSA) kinetics after radiation therapy plays a large role in the management of patients with prostate cancer (PCa). This is particularly true in establishing expectations regarding PSA nadir (nPSA) and PSA bounces, which can be disconcerting. As increasingly more patients are being treated with stereotactic body radiation therapy (SBRT) for low- and intermediate-risk PCa, it is imperative to understand the PSA response to SBRT.

      Methods and Materials

      PSA data from 5 institutions were retrospectively analyzed for patients with localized PCa treated definitively with SBRT alone from 2004 to 2016. Patients received 35 to 40 Gy in 5 fractions, per institutional standards. Patients who had less than 12 months of PSA data or received androgen deprivation therapy were excluded from this study. Linear and logistic multivariable analysis were performed to identify predictors of nPSA, bounce, and biochemical recurrence, and joint latent class models were developed to identify significant predictors of time to biochemical failure.


      A total of 1062 patients were included in this study. Median follow-up was 66 months (interquartile range [IQR], 36.4-89.9 months). Biochemical failure per the Phoenix criteria occurred in 4% of patients. Median nPSA was 0.2 ng/mL, median time to nPSA was 40 months, 84% of patients had an nPSA ≤0.5 ng/mL, and 54% of patients had an nPSA ≤0.2 ng/mL. On multivariable analysis, nPSA was a significant predictor of biochemical failure. Benign PSA bounce was noted in 26% of patients. The median magnitude of PSA bounce was 0.52 ng/mL (IQR, 0.3-1.0 ng/mL). Median time to PSA bounce was 18.1 months (IQR, 12.0-31.1 months). On multivariable analysis, age and radiation dose were significantly associated with a lower incidence of bounce. Joint latent class models modeling found that nPSA and radiation dose were significantly associated with longer time to biochemical failure.


      In this multi-institutional cohort of patients with long-term follow-up, we found that SBRT led to low nPSAs. In turn, lower nPSAs are associated with reduced incidence of, and longer time to, biochemical failure. Benign PSA bounces occurred in a quarter of patients, as late as several years after treatment. Further studies are needed to directly compare the PSA response of patients who receive SBRT versus other treatment modalities.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Carroll P.H.
        • Mohler J.L.
        NCCN Guidelines updates: Prostate cancer and prostate cancer early detection.
        J Natl Compr Canc Netw. 2018; 16: 620-623
        • Vogelius I.R.
        • Bentzen S.M.
        Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?.
        Int J Radiat Oncol Biol Phys. 2013; 85: 89-94
        • Dasu A.
        • Toma-Dasu I.
        Prostate alpha/beta revisited — An analysis of clinical results from 14 168 patients.
        Acta Oncol. 2012; 51: 963-974
        • Dearnaley D.
        • Syndikus I.
        • Mossop H.
        • et al.
        Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
        Lancet Oncol. 2016; 17: 1047-1060
        • Lee W.R.
        • Dignam J.J.
        • Amin M.B.
        • et al.
        Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer.
        J Clin Oncol. 2016; 34: 2325-2332
        • Catton C.N.
        • Lukka H.
        • Gu C.S.
        • et al.
        Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer.
        J Clin Oncol. 2017; 35: 1884-1890
        • Kishan A.U.
        • Dang A.
        • Katz A.J.
        • et al.
        Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer.
        JAMA Netw Open. 2019; 2: e188006
        • King C.R.
        • Collins S.
        • Fuller D.
        • et al.
        Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: Results from a multi-institutional consortium of prospective trials.
        Int J Radiat Oncol Biol Phys. 2013; 87: 939-945
        • Katz A.J.
        • Kang J.
        Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study.
        Front Oncol. 2014; 4: 301
        • Johnson S.B.
        • Soulos P.R.
        • Shafman T.D.
        • et al.
        Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
        Radiother Oncol. 2016; 121: 294-298
        • Baker B.R.
        • Basak R.
        • Mohiuddin J.J.
        • et al.
        Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.
        Cancer. 2016; 122: 2234-2241
        • Widmark A.
        • Gunnlaugsson A.
        • Beckman L.
        • et al.
        OC-0599: Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial.
        Radiother Oncol. 2018; 127: S314
        • Morrison K.
        • Tree A.
        • Khoo V.
        • et al.
        The PACE trial: International randomised study of laparoscopic prostatectomy vs. stereotactic body radiotherapy (SBRT) and standard radiotherapy vs. SBRT for early stage organ-confined prostate cancer.
        J Clin Oncol. 2018; 36 (TPS153-TPS)
        • Ray M.E.
        • Thames H.D.
        • Levy L.B.
        • et al.
        PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis.
        Int J Radiat Oncol Biol Phys. 2006; 64: 1140-1150
        • Sheinbein C.
        • Teh B.S.
        • Mai W.Y.
        • et al.
        Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer.
        Urology. 2010; 76: 728-733
        • Kataria S.
        • Koneru H.
        • Guleria S.
        • et al.
        Prostate-specific antigen 5 years following stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: An ablative procedure?.
        Front Oncol. 2017; 7: 157
        • Chen L.N.
        • Suy S.
        • Uhm S.
        • et al.
        Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience.
        Radiat Oncol. 2013; 8: 58
        • Romesser P.B.
        • Pei X.
        • Shi W.
        • et al.
        Prostate-specific antigen (PSA) bounce after dose-escalated external beam radiation therapy is an independent predictor of PSA recurrence, metastasis, and survival in prostate adenocarcinoma patients.
        Int J Radiat Oncol Biol Phys. 2018; 100: 59-67
        • Freiberger C.
        • Berneking V.
        • Vogeli T.A.
        • et al.
        Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
        Radiat Oncol. 2017; 12: 98
        • Hinnen K.A.
        • Monninkhof E.M.
        • Battermann J.J.
        • et al.
        Prostate specific antigen bounce is related to overall survival in prostate brachytherapy.
        Int J Radiat Oncol Biol Phys. 2012; 82: 883-888
        • Caloglu M.
        • Ciezki J.P.
        • Reddy C.A.
        • et al.
        PSA bounce and biochemical failure after brachytherapy for prostate cancer: A study of 820 patients with a minimum of 3 years of follow-up.
        Int J Radiat Oncol Biol Phys. 2011; 80: 735-741
        • Burchardt W.
        • Skowronek J.
        Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer.
        J Contemp Brachytherapy. 2018; 10: 1-9
        • Anwar M.
        • Weinberg V.
        • Chang A.J.
        • et al.
        Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: Comparison of PSA slope and nadir.
        Radiat Oncol. 2014; 9: 42
        • Kishan A.U.
        • Wang P.C.
        • Upadhyaya S.K.
        • et al.
        SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
        Pract Radiat Oncol. 2016; 6: 268-275
        • Johnson J.R.
        Methods for handling concentration values below the limit of quantification in PK studies.
        PhUSE US Connect. DH05, Raleigh, NC2018
        • Roach 3rd, M.
        • Hanks G.
        • Thames Jr., H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Proust-Lima C.
        • Sene M.
        • Taylor J.M.
        • et al.
        Joint latent class models for longitudinal and time-to-event data: A review.
        Stat Methods Med Res. 2014; 23: 74-90
        • R Core Team
        Pwr package in R: A language and environment for statistical computing.
        R Foundation for Statistical Computing, Vienna, Austria2018
        • Musunuru H.B.
        • Quon H.
        • Davidson M.
        • et al.
        Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials.
        Radiother Oncol. 2016; 118: 112-117
        • Alayed Y.
        • Cheung P.
        • Pang G.
        • et al.
        Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials.
        Radiother Oncol. 2018; 127: 213-218
        • Katz A.J.
        • Santoro M.
        • Diblasio F.
        • et al.
        Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.
        Radiat Oncol. 2013; 8: 118
        • Vu C.C.
        • Haas J.A.
        • Katz A.E.
        • et al.
        Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer.
        Front Oncol. 2014; 4: 8
        • Kim H.J.
        • Phak J.H.
        • Kim W.C.
        Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
        Prostate Int. 2015; 3: 118-122
        • Waters A.
        • Delouya G.
        • Donath D.
        • et al.
        Risk factors for PSA bounce following radiotherapy: Outcomes from a multi-modal therapy analysis.
        Can J Urol. 2014; 21: 7548-7553
        • Charret J.
        • Baumann A.S.
        • Eschwege P.
        • et al.
        Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor.
        Brachytherapy. 2018; 17: 888-894
        • Sweeney C.
        • Nakabayashi M.
        • Regan M.
        • et al.
        The development of intermediate clinical endpoints in cancer of the prostate (ICECaP).
        J Natl Cancer Inst. 2015; 107: djv261
        • Royce T.J.
        • Chen M.H.
        • Wu J.
        • et al.
        Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy vs radiation therapy plus androgen deprivation therapy: A secondary analysis of a randomized clinical trial.
        JAMA Oncol. 2017; 3: 652-658


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.